Software is no longer a supporting feature in much of medical technology. It is increasingly the product itself, responsible for interpreting data, guiding clinical decisions, monitoring patients, and shaping how care is delivered. That shift has created an attractive opportunity for MedTech companies, but it has also changed the development equation. A Software as a Medical Device, or SaMD, product cannot be managed like an ordinary software application with regulatory paperwork added shortly before launch. Its architecture, requirements, quality controls, risk management, testing strategy, documentation, and postmarket processes are tightly connected from the start. For teams preparing to build SaMD products, the quality management system is therefore not an administrative layer around development but one of the operating systems through which development must occur.<\/p>\n\n\n\n
That distinction is particularly important for manufacturers accustomed to treating quality management system, or QMS, activities as discrete compliance obligations. In SaMD development, requirements can change weekly, software versions may move through multiple releases, risk controls are often implemented in code, and verification evidence can be generated continuously. A QMS that depends on disconnected documents, manual approvals, and late-stage reconciliation can become an immediate constraint. The issue is not simply whether the organization possesses standard operating procedures. The more consequential question is whether those procedures, systems, and records can keep pace with the software development lifecycle while maintaining defensible traceability. Before a MedTech team writes production code, it should understand how its QMS will govern the product from concept through postmarket operation.<\/p>\n\n\n\n
The first major mistake teams make is treating the product idea as a technical specification rather than a regulatory proposition. Developers may describe a product in terms of features, workflows, algorithms, integrations, and user interfaces, while regulators focus on intended use, intended users, patient populations, medical purposes, and the consequences of incorrect output. Those distinctions determine far more than the language on a future submission. They influence classification, evidence expectations, risk-management activities, validation strategies, labeling, and the level of design control that will be required. A seemingly modest wording change in an intended-use statement can move a product into a substantially different regulatory position. For that reason, regulatory strategy and product definition should develop together rather than in separate organizational lanes.<\/p>\n\n\n\n
This is where early QMS implementation becomes operationally important. An organization needs controlled mechanisms for establishing design inputs, documenting assumptions, approving intended-use language, linking user needs to product requirements, and recording why significant design decisions were made. Those records create the foundation for traceability later in the development cycle. They also prevent the product team from informally expanding the product’s claims without understanding the regulatory consequences. If engineers, clinicians, product managers, and regulatory personnel are working from different definitions of what the software is supposed to do, no document-management system can repair the underlying problem. A functioning QMS should therefore make the regulatory product definition visible, controlled, and connected to the requirements that engineers actually implement.<\/p>\n\n\n\n
Managing those connections across an evolving software-development program has increased interest in purpose-built regulatory technology, particularly tools that connect regulatory requirements, traceability, and submission activities with the development process itself. One example is Enlil, a platform that applies Agentic AI to MedTech regulatory submissions and helps teams maintain traceability and compliance as development progresses. For organizations working through SaMD requirements, the company has published a guide<\/a> explaining how FDA expectations apply to Software as a Medical Device. Such resources can provide context as teams shape their regulatory approach. They can also make complex regulatory information easier to manage across development activities. Still, they do not replace the manufacturer\u2019s responsibility to define intended use, document risks, establish appropriate evidence, and maintain effective quality controls throughout the product lifecycle.<\/p>\n\n\n\n Traditional medical-device quality systems were often built around relatively stable physical products. Design documentation moved through recognizable phases, manufacturing processes were validated, physical components were controlled, and changes could be handled through formal engineering-change mechanisms. Software moves at a different tempo. Development teams may work in short iterations, merge code several times a day, maintain parallel environments, deploy patches rapidly, and adjust requirements as usability or technical findings emerge. When QMS procedures assume long document cycles and infrequent changes, teams are forced to choose between productivity and procedural compliance. That is usually a sign that the QMS has been implemented around paperwork rather than around actual operational risk.<\/p>\n\n\n\n A modern SaMD QMS should support iterative development without abandoning control. Requirements can evolve, but changes need documented rationale and impact analysis. Code can be released frequently, but each release should be associated with an approved configuration, test evidence, risk assessment, and defined acceptance criteria. Automated testing can reduce manual verification effort, but automation itself must be governed sufficiently to make the resulting evidence trustworthy. Electronic approvals can accelerate workflows, but roles, permissions, timestamps, and audit trails need appropriate controls. The objective is not to recreate a waterfall development model inside a digital QMS. It is to establish controls that remain effective when development operates continuously.<\/p>\n\n\n\n This is why QMS implementation should involve engineering leadership rather than being delegated exclusively to quality or regulatory affairs. Developers need to understand which activities generate controlled records, where traceability is required, how software configuration is identified, and when a change requires formal review. Quality teams, in turn, need enough understanding of software engineering to avoid imposing processes that generate documentation without improving product assurance. The best systems reduce duplicate entry by allowing evidence to flow from development activities into controlled quality records. They also distinguish between low-value administrative events and decisions that materially affect safety, performance, security, or regulatory claims. When the QMS reflects the development lifecycle, compliance becomes a property of the workflow rather than a separate project.<\/p>\n\n\n\n Traceability is one of the defining disciplines of regulated software development. A MedTech company should be able to demonstrate how user needs translate into system and software requirements, how those requirements connect to identified hazards and risk controls, how implementation addresses the requirements, and how verification or validation confirms expected performance. That chain becomes difficult to reconstruct when it is distributed across spreadsheets, ticketing systems, test repositories, shared drives, email threads, and informal engineering conversations. The problem typically becomes visible late, when a submission is being assembled or an audit is approaching. By that stage, the organization may spend weeks trying to recreate decisions that were obvious to the team months earlier. A better approach is to make traceability a routine output of development.<\/p>\n\n\n\n Implementing traceability effectively requires more than purchasing requirements-management software. Teams first need a consistent information model defining how user needs, design inputs, software requirements, hazards, controls, tests, defects, changes, and releases relate to one another. They also need ownership rules that determine who creates, reviews, approves, and updates each record type. The QMS should explain when links are mandatory and how broken or incomplete relationships are identified. Automated reporting can then expose gaps, such as a requirement without a verification test or a risk control that has not been confirmed. Without that underlying governance, a sophisticated digital platform can still produce an impressive but unreliable traceability matrix.<\/p>\n\n\n\n Strong traceability also improves development decisions before regulators ever see the records. When a requirement changes, teams can identify the affected tests, hazards, documentation, interfaces, and released configurations more quickly. When a defect is discovered, investigators can determine whether it undermines a safety control or invalidates prior verification. When a release candidate is evaluated, decision-makers can see whether critical requirements have adequate evidence rather than relying on broad assurances that testing is complete. Traceability therefore has economic value in addition to regulatory value. It reduces the cost of change by making dependencies visible. For SaMD companies expected to release software repeatedly, that capability can become a competitive advantage.<\/p>\n\n\n\n SaMD risk management is frequently weakened when hazard analysis is treated as a regulatory document that is updated periodically instead of as an active engineering input. Software hazards may arise from incorrect calculations, delayed information, misleading displays, unavailable functions, interoperability failures, corrupted data, inappropriate user actions, cybersecurity events, or combinations of faults across systems. Many of these hazards are directly affected by design decisions made during ordinary development. If the risk file is disconnected from issue tracking and requirements management, engineers can modify behavior without understanding that they are modifying a risk control. The regulatory consequence is incomplete risk documentation, but the more important consequence is reduced visibility into product safety. Risk management should be embedded in the design process rather than scheduled around submission milestones.<\/p>\n\n\n\n A well-implemented QMS establishes explicit connections between hazards, hazardous situations, harms, risk estimations, controls, verification evidence, and residual-risk decisions. When a risk control is implemented in software, the corresponding software requirement should be identifiable. Its verification should be documented, and changes affecting that requirement should trigger appropriate review. Teams should also define how defects are screened for risk significance because not every software bug has the same regulatory or clinical meaning. A cosmetic issue and a fault that could generate an incorrect therapeutic recommendation should not travel through identical decision pathways. The QMS needs enough structure to distinguish those cases consistently. That structure is particularly important as the number of software versions and postmarket signals grows.<\/p>\n\n\n\n The quality system should also establish how risk information feeds other processes. Complaints may reveal hazards that were underestimated during development. Cybersecurity monitoring may expose new threat scenarios that alter risk controls. Usability testing may reveal foreseeable misuse that was not obvious from early design analysis. Production and post-production information should therefore flow back into the risk-management process rather than remaining isolated in separate databases. This feedback loop helps keep the risk file aligned with the product that is actually in the market. For SaMD, where software behavior can change substantially between versions, a static risk file quickly becomes a historical artifact rather than a management tool.<\/p>\n\n\n\n SaMD teams often speak broadly about “testing,” but regulated development requires greater precision. Verification asks whether specified requirements were correctly implemented. Validation asks whether the resulting product meets user needs and intended uses in the actual or simulated environment of use. These activities may overlap operationally, but they answer different questions and often require different evidence. Unit tests, integration tests, system tests, performance tests, security tests, usability evaluations, and clinical validation activities should therefore be planned according to the claims and risks of the product. A large quantity of test results does not compensate for testing the wrong things. The QMS should make the purpose and acceptance criteria of testing explicit.<\/p>\n\n\n\n Automation changes how that evidence can be generated but does not eliminate governance requirements. Continuous integration pipelines may run thousands of tests following a software change, creating a far stronger evidence stream than periodic manual testing could provide. Yet the organization still needs confidence that the tests are appropriate, maintained, correctly configured, and associated with controlled software versions. Failed tests must be handled consistently, and changes to testing infrastructure may themselves need evaluation. The QMS should define which automated outputs constitute quality records and how they are retained. It should also prevent teams from confusing a successful pipeline with comprehensive product validation. Automated technical verification is powerful, but it does not answer every clinical, usability, or real-world question.<\/p>\n\n\n\n Validation becomes especially important when product value depends on user interpretation or clinical context. A software function can perform exactly as programmed and still fail to support the intended medical purpose. Interfaces may technically display correct information while causing users to misunderstand urgency or significance. Algorithms may achieve favorable analytical performance while performing differently in the intended patient population. Workflow assumptions may prove unrealistic in busy clinical environments. A mature QMS makes these uncertainties visible through documented validation planning rather than leaving them to informal product judgment. Teams should know what evidence will be required to support intended use long before the final software build is available.<\/p>\n\n\n\n Software products are defined by versions, dependencies, libraries, infrastructure, configuration settings, interfaces, databases, and deployment environments. A regulatory submission or design-history record that refers simply to “the software” without a precise configuration creates ambiguity. Teams need to know exactly which version was tested, which requirements applied to it, which unresolved anomalies were present, and which supporting components were part of the released configuration. Configuration management is therefore not merely an engineering convenience. It is fundamental to demonstrating that the evidence in the QMS corresponds to the product that was actually released. As software ecosystems become more complex, that relationship becomes increasingly difficult to manage manually.<\/p>\n\n\n\n Change control must be similarly proportionate and disciplined. SaMD products inevitably change because teams correct defects, update libraries, improve cybersecurity, modify interfaces, optimize algorithms, add features, or respond to customer feedback. The QMS should define how those changes are assessed for impact on safety, effectiveness, validation, risk controls, documentation, regulatory status, and previously generated evidence. Minor changes should not require unnecessarily burdensome processes, but the organization needs objective criteria for deciding what is minor. A seemingly small code modification can have broad downstream effects if it touches shared logic or a critical calculation. Digital QMS workflows are most valuable when they make those dependencies visible before approval.<\/p>\n\n\n\n Release management is where many of these controls converge. Before a version is distributed, an organization should be able to identify the approved requirements, completed verification, validation status, known anomalies, cybersecurity findings, unresolved risks, labeling, and formal release authorization associated with that build. If the release decision requires manual collection of information from numerous systems, omissions become more likely. A better implementation pulls key evidence into a controlled release record with clear ownership and approval criteria. This does not mean every technical artifact must be duplicated inside the QMS. It means the QMS must retain or reference enough controlled evidence to reconstruct the release decision reliably. Regulators and auditors ultimately need confidence that the organization knew what it was releasing and why it considered the product acceptable.<\/p>\n\n\n\n Cybersecurity can no longer be managed as a technical specialty outside the QMS. Connected medical software depends on operating systems, networks, cloud services, third-party libraries, APIs, identity systems, and other components that introduce security risks throughout the product lifecycle. Vulnerabilities can emerge after release even when the original software passed all premarket tests. That means cybersecurity controls need relationships to design inputs, risk management, supplier management, change control, complaint handling, corrective and preventive action, and postmarket surveillance. A security process that exists only in engineering documentation will eventually collide with regulatory processes when a vulnerability requires field action. The QMS should establish that connection before an incident occurs.<\/p>\n\n\n\n Software bills of materials, vulnerability assessments, penetration testing, access-control requirements, threat modeling, security updates, and coordinated vulnerability disclosure all generate information that may need controlled treatment. Manufacturers should define who reviews newly disclosed vulnerabilities and how they determine whether the affected component is present in a released product. They should also establish thresholds for escalation and documentation. In mature organizations, security findings feed risk assessments and release decisions in a repeatable manner. The objective is not to eliminate all vulnerabilities, which is unrealistic for complex software. The objective is to demonstrate a systematic process for identifying, evaluating, controlling, and monitoring cybersecurity risk.<\/p>\n\n\n\n Third-party and open-source components create an additional QMS challenge because much of modern software is assembled from external dependencies. Teams may not control the development practices of those suppliers, but they remain responsible for the medical device they place on the market. Supplier controls should therefore reflect the actual significance of external software rather than relying only on traditional purchasing procedures. Critical dependencies may require documented evaluation, version monitoring, security surveillance, and contingency planning. Updates should be assessed for both the risk of adopting them and the risk of delaying them. A QMS designed around physical suppliers alone may not capture these relationships adequately. SaMD manufacturers need supplier-management processes that recognize code and cloud infrastructure as essential components of the product ecosystem.<\/p>\n\n\n\n SaMD development does not end when the first version is released. Software products produce a continuing stream of information through support requests, complaints, telemetry, defect reports, security alerts, performance monitoring, and user feedback. That data can reveal safety problems or performance trends that were not detectable during premarket testing. If postmarket processes have not been designed in advance, organizations may collect large quantities of information without a consistent method for evaluating its regulatory significance. The QMS should define how incoming signals are categorized, investigated, trended, escalated, and connected to corrective action. It should also distinguish ordinary technical support from events that may constitute reportable complaints or safety issues.<\/p>\n\n\n\n Digital products can provide manufacturers with unusually rich postmarket visibility, but more data creates its own governance problem. Telemetry may show error rates, workflow abandonment, unusual usage patterns, or system outages long before customers file formal complaints. Teams need criteria for determining when those signals require quality-system action. Algorithms and decision-support functions may also need ongoing performance monitoring to detect drift or population-specific weaknesses. The organization should decide which metrics matter and who is responsible for reviewing them. If thresholds are defined only after an adverse trend appears, decisions can become inconsistent and difficult to defend. Postmarket surveillance should therefore be treated as part of product architecture and quality planning, not merely as a regulatory reporting function.<\/p>\n\n\n\n Corrective and preventive action, or CAPA, should likewise connect directly to software development. A recurring defect may reveal an inadequate requirement, ineffective review practice, weak automated test, training problem, or architectural limitation. Closing the individual bug without addressing the systemic cause can allow the same failure mechanism to reappear. The QMS should support investigation at the appropriate level and link CAPA activities to changes in procedures, requirements, testing, training, or technical controls. Software organizations sometimes resist CAPA because poorly designed processes can become slow and bureaucratic. The answer is not to avoid formal corrective action, but to build a risk-based process that distinguishes systemic quality problems from routine software maintenance. A disciplined system helps organizations learn from failures instead of merely patching them.<\/p>\n\n\n\n Choosing QMS software is often treated as an information-technology procurement decision, but for SaMD companies it is closer to an operating-model decision. The platform will influence how requirements are approved, how changes are reviewed, how training is documented, how CAPAs are investigated, how suppliers are controlled, and how evidence is assembled for audits and submissions. Implementing a poorly aligned platform can create more administrative work than the paper processes it replaced. Teams should therefore map critical workflows before configuring the system. They need to understand which records belong in the QMS, which can remain in engineering systems, and how authoritative links will be maintained between them. Technology should support the quality architecture rather than determine it by default.<\/p>\n\n\n\n Integration deserves particular attention because engineering teams already work in specialized environments. Source control, issue tracking, test automation, requirements tools, cybersecurity platforms, cloud infrastructure, and customer-support systems may all contain evidence relevant to the quality system. Requiring employees to reproduce that information manually inside QMS software introduces delay and transcription risk. A stronger model preserves technical work in the tools best suited to it while creating controlled relationships to quality records. That approach requires clear governance regarding data ownership, system validation, permissions, audit trails, and retention. Integration should reduce duplication without creating ambiguity about which system contains the authoritative record.<\/p>\n\n\n\n Implementation should also be measured by operational outcomes rather than by the number of workflows configured. Useful metrics may include requirement-traceability completeness, change-review cycle time, verification coverage, overdue quality actions, CAPA aging, supplier-review status, audit findings, and time required to assemble release evidence. If teams routinely bypass the QMS because it slows development, that is a management signal rather than simply an employee-compliance problem. Processes may be poorly designed, responsibilities may be unclear, or the technology may not match the organization’s development model. Quality leaders should treat QMS performance as a system that can itself be improved. For SaMD businesses operating under rapid release cycles, unnecessary friction eventually becomes both a compliance risk and a commercial cost.<\/p>\n\n\n\n The most important lesson for MedTech teams is that quality cannot be added to SaMD after the software has been built. Regulatory strategy influences intended use, intended use influences requirements, requirements connect to risks, risks shape controls, controls require verification, and every released configuration needs evidence that those relationships remain intact. The QMS is what gives those connections organizational continuity. When it is weak, teams depend on individual memory and heroic document-reconstruction efforts. When it is strong, regulatory evidence emerges naturally from controlled development activities. That difference becomes increasingly important as the product grows, personnel change, and release frequency increases.<\/p>\n\n\n\n This does not require turning software engineers into regulatory specialists or asking quality teams to manage every line of code. It requires agreement on the boundaries between engineering systems and quality systems, along with reliable mechanisms for connecting the two. Developers should know when their work creates a regulated design change. Quality professionals should understand how automated testing, source control, configuration management, and continuous delivery generate evidence. Regulatory teams should be involved early enough to prevent product claims from drifting away from the documented intended use. Management should have visibility into unresolved quality and risk issues before they become release emergencies. A well-designed QMS creates those conditions without making every development activity a bureaucratic event.<\/p>\n\n\n\n For executives, the economic implications are substantial. A company that delays quality-system maturity may appear to move quickly during early development, only to encounter major rework when preparing a regulatory submission, responding to an audit, investigating a field issue, or pursuing a new market. Missing traceability, inconsistent design records, undocumented changes, and incomplete verification evidence become expensive precisely when the business has the least appetite for delay. Conversely, a QMS built around the realities of SaMD development can make future releases, regulatory submissions, diligence exercises, and postmarket investigations more predictable. The strategic question is therefore not how little quality infrastructure a young MedTech company can tolerate. It is how early the company can build a quality system that allows the software organization to scale without losing control of the evidence behind the product.<\/p>\n","protected":false},"excerpt":{"rendered":" Software is no longer a supporting feature in much of medical technology. It is increasingly the product itself, responsible for interpreting data, guiding clinical decisions, monitoring patients,… <\/p>\n","protected":false},"author":65,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_joinchat":[],"footnotes":""},"categories":[11138],"tags":[],"class_list":["post-78538","post","type-post","status-publish","format-standard","hentry","category-best-tools"],"_links":{"self":[{"href":"https:\/\/www.devopsschool.com\/blog\/wp-json\/wp\/v2\/posts\/78538","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.devopsschool.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.devopsschool.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.devopsschool.com\/blog\/wp-json\/wp\/v2\/users\/65"}],"replies":[{"embeddable":true,"href":"https:\/\/www.devopsschool.com\/blog\/wp-json\/wp\/v2\/comments?post=78538"}],"version-history":[{"count":1,"href":"https:\/\/www.devopsschool.com\/blog\/wp-json\/wp\/v2\/posts\/78538\/revisions"}],"predecessor-version":[{"id":78539,"href":"https:\/\/www.devopsschool.com\/blog\/wp-json\/wp\/v2\/posts\/78538\/revisions\/78539"}],"wp:attachment":[{"href":"https:\/\/www.devopsschool.com\/blog\/wp-json\/wp\/v2\/media?parent=78538"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.devopsschool.com\/blog\/wp-json\/wp\/v2\/categories?post=78538"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.devopsschool.com\/blog\/wp-json\/wp\/v2\/tags?post=78538"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}<\/a>The QMS Must Fit the Software Development Lifecycle<\/strong><\/h2>\n\n\n\n
<\/a>Traceability Must Be Designed Into the Product Program<\/strong><\/h2>\n\n\n\n
<\/a>Risk Management Cannot Be a Separate Spreadsheet Exercise<\/strong><\/h2>\n\n\n\n
<\/a>Verification and Validation Need Different Questions and Evidence<\/strong><\/h2>\n\n\n\n
<\/a>Configuration and Change Control Determine Whether Records Remain Defensible<\/strong><\/h2>\n\n\n\n
<\/a>Cybersecurity Has Become a Quality-System Responsibility<\/strong><\/h2>\n\n\n\n
<\/a>Postmarket Operations Should Be Designed Before Launch<\/strong><\/h2>\n\n\n\n
<\/a>QMS Software Should Reduce Compliance Friction, Not Digitize Bureaucracy<\/strong><\/h2>\n\n\n\n
<\/a>Successful SaMD Programs Treat Quality as Product Infrastructure<\/strong><\/h2>\n\n\n\n